Rapid response to selpercatinib in RET fusion positive pancreatic neuroendocrine carcinoma confirmed by smartwatch

Abstract This case report describes the efficacy of selpercatinib, a selective RET inhibitor, in an unusual case of large-cell neuroendocrine pancreatic carcinoma (LCNEPAC) harboring a CCDC6::RET fusion. A 56-year-old male with a history of multiple lines of systemic therapies exhibited marked clini...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Barbara Deschler-Baier, Markus Krebs, Matthias Kroiss, Manik Chatterjee, Daniel Gundel, Christian Kestler, Alexander Kerscher, Volker Kunzmann, Silke Appenzeller, Katja Maurus, Andreas Rosenwald, Ralf Bargou, Elena Gerhard-Hartmann, Vivek Venkataramani
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Nature Portfolio 2024-07-01
Serie:	npj Precision Oncology
Accesso online:	https://doi.org/10.1038/s41698-024-00659-x
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!